GENB logo

GENB
Generate Biomedicines Inc

74
Mkt Cap
$1.47B
Volume
205,381.00
52W High
$15.32
52W Low
$11.00
Price
$11.53
GENB Fundamentals
Prev Close
$11.94
Open
$12.00
50D MA
$12.25
Beta
0.00
Avg. Volume
634,885.99
EPS (Annual)
-$4.98
Rev/Employee
$102,221.15
Loading...
Loading...
News
all
press releases
Generate Biomedicines (NASDAQ:GENB) Trading Down 6.9% - Time to Sell?
Generate Biomedicines (NASDAQ:GENB) Shares Down 6.9% - Time to Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Generate Biomedicines Inc's Quiet Period To End on April 8th (NASDAQ:GENB)
Generate Biomedicines' (NASDAQ:GENB - Get Free Report) quiet period will end on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its IPO on February 27th. The total size of...
MarketBeat·9d ago
News Placeholder
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Recommendation of "Buy" from Analysts
Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) has received an average recommendation of "Buy" from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year...
MarketBeat·16d ago
News Placeholder
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB)
The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research note on Tuesday. They issued a "buy" rating and a $26.00 price target on the stock...
MarketBeat·17d ago
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Piper Sandler
Piper Sandler began coverage on Generate Biomedicines in a research note on Tuesday. They issued an "overweight" rating and a $24.00 price target on the stock...
MarketBeat·17d ago
News Placeholder
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB)
Morgan Stanley assumed coverage on Generate Biomedicines in a research note on Tuesday. They set an "overweight" rating and a $20.00 price objective for the company...
MarketBeat·17d ago
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim
Guggenheim initiated coverage on shares of Generate Biomedicines in a research note on Tuesday. They set a "buy" rating and a $30.00 price target on the stock...
MarketBeat·17d ago
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a report on Tuesday. They set an "overweight" rating on the stock...
MarketBeat·17d ago
News Placeholder
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised Generate Biomedicines to a "hold" rating in a report on Saturday...
MarketBeat·27d ago
News Placeholder
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering PR Newswire SOMERVILLE, Mass., Feb. 26, 2026...
PR Newswire·1mo ago
<
1
2
...
>

Latest GENB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.